Clinical Research

Sling Therapeutics Inc.

Address
455 East Eisenhower Parkway Suite 300, Pmb 1048

Sponsor Overview

assignment
2
sponsored trials
science
1
molecule
location_city
4
research centres
public
2
countries
person_search
6
investigators

Specializations

Thyroid Eye Disease

Sling Therapeutics Inc. focuses clinical research on active, moderate to severe thyroid eye disease, with attention to the orbital and inflammatory features that drive eye protrusion and visual discomfort.

  • Proptosis
  • Orbital inflammation
  • Active thyroid eye disease

The sponsor’s studies are centered on outcomes relevant to eye bulging and disease activity in patients with TED.

Ophthalmic Disease Activity

Its research landscape includes clinical evaluation of changes in eye prominence and related signs of disease progression in ophthalmology.

  • Eye protrusion
  • Clinical response assessment
  • Contralateral eye stability

These areas reflect a therapeutic interest in measurable eye-specific outcomes for patients with thyroid-associated orbitopathy.

Endocrine-Related Autoimmune Disease

The sponsor’s trial portfolio also aligns with the treatment of autoimmune conditions linked to thyroid dysfunction, particularly those with prominent ocular involvement.

  • Autoimmune eye disease
  • Thyroid-associated orbitopathy
  • Inflammatory eye manifestations

Research activity is concentrated on therapeutic approaches for disease presentations that combine endocrine and ocular pathology.

Targeted Therapeutic Development

Sling Therapeutics Inc. is engaged in clinical development around a targeted approach for TED, with interest in assessing treatment effects on patient-relevant ocular endpoints.

  • Linsitinib
  • Therapeutic response in TED
  • Moderate to severe disease management

Its research activity is concentrated in clinical operations supporting studies in the United States and other active trial settings.

Sponsored Trials

Trial Name Country Status
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)Italy ItalySpain SpainNot Recruiting
Phase 2b Randomized Double-Mask Placebo-Controlled Trial of Linsitinib in Active Moderate to Severe Thyroid Eye DiseaseItaly ItalySpain SpainNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 1 total (100% not shared with other sponsors)

This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
100%
Return partnership rate
4 of 4 sites collaborated multiple times

This sponsor has worked with 4 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Eye Diseases2 trials
    138 other sponsors

Partnered Research Centres

4 centres
location_city
assignment364
Bellvitge University Hospital
Address
Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
Learn morearrow_forward
location_city
assignment563
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Address
Via Francesco Sforza 28, 20122 Milan
Learn morearrow_forward
location_city
assignment332
Hospital Universitario De La Princesa
Address
Calle De Diego De Leon 62, 28006 Madrid
Learn morearrow_forward
location_city
assignment225
Universita' Di Pisa
Address
Via Roma 67, 56126 Pisa
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Sling Therapeutics Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.